Welchol Related Published Studies
Well-designed clinical trials related to Welchol (Colesevelam)
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. [2008.10.13]
Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. [2006.09.01]
Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. [2006.04]
Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. [2005.09]
Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. [2005.07]
Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. [2005.07]
Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. [2004]
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. [2001.10]
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. [2001.10]
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. [2001.06]
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. [2001.04.01]
Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. [1999.09.13]
Other research related to Welchol (Colesevelam)
Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. [2008.08]
Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. [2008.07.28]
Colesevelam HCl Improves Glycemic Control and Reduces LDL-Cholesterol in Patients with Type 2 Diabetes Inadequately Controlled on Sulfonylurea-Based Therapy. [2008.05.05]
Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. [2008.04]
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. [2007.10]
Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. [2007.07]
Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. [2007.01]
Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. [2007.01]
Colesevelam: a review of its use in hypercholesterolemia. [2007]
Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. [2006.12]
Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. [2006.11]
Colesevelam hydrochloride in the management of dyslipidemia. [2006.05]
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. [2006.04.15]
Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. [2005.07.08]
Colesevelam: potential uses for the newest bile resin. [2005.03]
Dietary administration of colesevelam hydrochloride does not affect fertility or reproductive performance in rats. [2004.11]
Colesevelam HCl: a non-systemic lipid-altering drug. [2003.05]
Colesevelam hydrochloride. [2002.05.15]
Absorption of colesevelam hydrochloride in healthy volunteers. [2002.03]
Effect of colesevelam on lovastatin pharmacokinetics. [2002.03]
Colesevelam hydrochloride: a novel bile acid-binding resin. [2001.07]
Colesevelam: a new bile acid sequestrant. [2001.01]
Colesevelam. [2001]
Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. [2000.12]
Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. [2000.11]
Other possibly related research studies
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. [2005.08.22]
Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. [2004.09.15]
Overview of pharmacologic therapy for the treatment of dyslipidemia. [2003.01]
Identifying effective and/or safe doses by stepwise confidence intervals for ratios. [2003.03.30]
Absorption, distribution and excretion of GT31-104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration. [1997.05]
New drugs for the treatment of hypercholesterolaemia. [2003.11]
What's new in lipid management? [2003.09]
[New antilipemics: prospects] [2003.01]
Gateways to clinical trials. [2002.11]
Drug-induced effects on cholesterol catabolism and bile acids. [2006.03]
Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. [2006.03]
Lipid-lowering drugs. [2006.05]
Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. [2006.06]
Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. [2007.08]
Safety considerations with gastrointestinally active lipid-lowering drugs. [2007.03.19]
Bile acid sequestrants and the treatment of type 2 diabetes mellitus. [2007]
The 'forgotten' bile acid sequestrants: is now a good time to remember? [2007.11]
Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. [2008.06]
|
